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Germline anomalies of the INK4a-ARF and Cdk4 genes were sought in a series of 89 patients suspected of having a genetic
predisposition to melanoma. Patients were selected based on the following criteria: (a) familial melanoma (23 cases), (b) multiple
primary melanoma (MPM; 18 cases), (c) melanoma and additional unrelated cancers (13 cases), (d) age at diagnosis less than 25 years
(21 cases), and (e) nonphoto-induced melanoma (NPIM; 14 cases). Mutations of INK4a-ARF and Cdk4 were characterised by
automated sequencing, and germline deletions of INK4a-ARF were also examined by real-time quantitative PCR. Seven germline
changes of INK4a-ARF, five of which were novel, were found in seven patients (8%). Four were very likely to be pathogenic mutations
and were found in three high-risk melanoma families and in a patient who had a pancreatic carcinoma in addition to melanoma. Three
variants of uncertain significance were detected in one MPM patient, one patient o25 years, and one NPIM patient. No germline
deletion of INK4a-ARF was found in 71 patients, and no Cdk4 mutation was observed in the 89 patients. This study confirms that
INK4a-ARF mutations are infrequent outside stringent familial criteria, and that germline INK4a-ARF deletions are rarely involved in
genetic predisposition to melanoma.
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Familial melanomas comprise from 8 to 12% of all cutaneous
malignant melanoma cases (Greene, 1999). Two highly penetrant
melanoma-predisposing genes have been identified to date, INK4a-
ARF and Cdk4 (Hussussian et al, 1994; Kamb et al, 1994; Zuo et al,
1996).
The INK4a-ARF gene on chromosome 9p21 encodes two
structurally distinct tumour-suppressor proteins by virtue of
different 50 exons spliced in different reading frames to common
exons 2 and 3. Exons 1a, 2, and 3 encode p16
INK4a, while exon 1b,
spliced to exons 2 and 3 in a different reading frame and
transcribed using a different promoter, encodes p14
ARF protein
(ARF, also called p19
ARF in mice). P16
INK4a is part of the G1–S cell
cycle checkpoint mechanism that involves the retinoblastoma-
susceptibility tumour suppressor protein (pRB). PRB protein, in its
unphosphorylated state, inhibits the progression of the cell cycle
from the G1 to the S phase by sequestering the transcription factor
E2F1. Phosphorylation of pRB by the cyclin-dependent-kinases
CDK4 and 6 (CDK4-6/D kinases) releases E2F1 and allows
progression through the G1–S checkpoint. P16
INK4a is a specific
inhibitor of CDK4 and 6, and thus, inactivation of p16
INK4a allows
cells to escape cell cycle arrest in G1.
The other product of the INK4a-ARF locus, p14
ARF, also acts as a
tumour suppressor (Sherr, 2000). Mice lacking ARF, but with
intact p16
INK4a, develop tumours (Kamijo et al, 1997), while
transfection of ARF into some carcinoma cell lines results in
marked growth inhibition (Simon et al, 1999; Yang et al, 2000).
ARF mediates G1 and G2 arrest at least partly by its interaction
with MDM2, a protein that binds to both TP53 and pRB. MDM2
targets TP53 for degradation by ubiquitination (Ashcroft and
Vousden, 1999) and also inhibits pRB growth-regulatory function.
ARF binds to MDM2 and promotes its degradation (Pomerantz
et al, 1998; Zhuang et al, 1998), resulting in stabilisation and
accumulation of TP53 protein and also of its downstream target
p21, an inhibitor not only of CDK4 and 6 but also of other CDKs.
Multiple studies have shown that germline mutations in the
INK4a-ARF gene are found on average in approximately 25% of
melanoma-prone families (reviewed in (Hayward, 2000; Piepkorn,
2000). The frequency of INK4a-ARF mutations in melanoma
probands increases with (i) the number of affected relatives, (ii)
the presence of multiple melanomas in the same patient, (Soufir
et al, 1998a; Holland et al, 1999) and (iii) a history of pancreatic
cancer cases in the family (Goldstein et al, 1995).
In contrast, mutations of Cdk4 appear to be a rare cause of
inherited susceptibility to melanoma. Four germline alterations
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shave been described in Cdk4 to date, in four melanoma-prone
kindreds (Zuo et al, 1996; Soufir et al, 1998a; Holland et al, 1999)
and in one melanoma patient with no known family history
(Guldberg et al, 1997). Two mutations occur in exon 2 of cdk4 at
the same codon (Arg24Cys, Arg24His) and functional analysis of
the Arg24Cys mutant protein reveals that it is deficient in binding
to p16
INK4a, but is capable of binding cyclin D and phosphorylat-
ing pRB.
Whereas germline mutations in the INK4a-ARF gene are
uncommon in unselected melanoma patients from the general
population (Aitken et al, 1999), the prevalence of INK4a-ARF
mutations in patients suspected of having a genetic predisposition
to melanoma outside a familial context remains to be clarified.
Therefore, in this work, we hypothesise that in addition to
patients with familial melanoma, some patients could have an
inherited predisposition to melanoma and might harbour germline
mutations of INK4a-ARF. These patients include those who had
multiple primary melanomas (MPM), melanoma associated with
another cancer, melanoma developing at a young age, or
nonphoto-induced melanomas (NPIM).
This hypothesis is strengthened by the fact that germline
mutations of the INK4a-ARF gene have been detected in some
MPMs (MacKie et al, 1998; Monzon et al, 1998; Hashemi et al,
2000; Auroy et al, 2001), and could also predispose to other types
of cancers, such as pancreatic cancer (Borg et al, 2000),
epidermoid carcinoma (Yarbrough et al, 1996), breast cancer
(Borg et al, 2000), or multiple myeloma (Dilworth et al, 2000) in
melanoma families.
The proposition that patients who develop melanoma at a young
age harbour a strong predisposition to melanocyte neoplasia is
consistent with Knudson’s hypothesis that cancers arising at a very
young age may result from mutations to key regulatory genes
passed through the germline model for the incidence of
retinoblastoma. Finally, melanomas considered to be nonphoto-
induced (NPIM) include (i) melanomas located on nonphoto-
exposed sites (sun-protected skin areas or mucous localisations)
and (ii) subungual and acral lentiginous melanomas that are
considered to be particular subtypes of melanoma, because, in
contrast to other subtypes, ultraviolet irradiation is not a major
factor in their development (Kato et al, 1996; Saida, 2001), thus
suggesting genetic factors in their onset.
Therefore, the specific aim of this study was to assess the
prevalence of INK4a-ARF and Cdk4 mutations among different
subgroups of patients with a possible hereditary predisposition to
melanoma. Here, we report that INK4a-ARF mutations are
predominantly found in high-risk melanoma kindreds, confirming
previous reports. However, we also found that INK4a-ARF
mutations are rarely present in individuals with suspected genetic
predisposition to melanoma (MPM, melanoma arising before the
age of 25 years, NPIM) without a family history of melanoma.
PATIENTS AND METHODS
Selection of patients
The present study was performed from 1999 to September 2002.
Patients were enrolled at the Saint Louis (50%), Bichat-Claude
Bernard (45%), Ambroise Pare ´ (5%), and Percy Hospitals (5%),
which are located in or near Paris city. In all, 89 patients were
prospectively enrolled in the study, of which 10% were incident
cases. The inclusion criteria were: (1) familial melanoma (FAM; 23
cases) defined as the presence of at least two melanoma cases in
first- or second-degree relatives (all cases confirmed by patholo-
gical reports); (2) multiple primary melanomas (MPM) defined as
the presence of at least two primary melanomas in the same patient
confirmed by pathological reports (18 cases); (3) melanoma in
young patients defined as melanoma in patients younger than 25
years (21 cases); (4) nonphoto-induced melanoma (14 cases)
defined by either melanomas located on nonphoto-exposed sites
(sun-protected skin areas or mucous localisations), and/or
subungual and acral lentiginous melanomas, which are considered
to be particular subtypes of melanoma; and (5) melanoma
associated with another cancer (13 cases). For familial melanoma
cases, only the proband was enrolled.
Written informed consent allowing peripheral blood sampling
and genetic analysis was obtained for each patient enrolled in the
study. Adoption and xeroderma pigmentosum cases were ex-
cluded.
For each patient included, clinical information was obtained by
a dermatologist and from medical records: family history of
melanoma, age at diagnosis of melanoma, tumour location,
histopathological classification and Breslow thickness, diagnosis
of multiple primary melanomas or other cancer, nevus count, and
the presence of clinically atypical mole syndrome (AMS), defined
as at least 50 nevi 42mm in diameter and including at least three
atypical nevi.
DNA PCR and sequencing
Genomic DNA was extracted from peripheral blood lymphocytes
as described by Miller et al (1988). The INK4a-ARF locus
comprises four exons, coding for two alternative transcripts:
p16
INK4a (exons 1a, 2 and 3) and p14
ARF (exons 1b, 2 and 3). PCR
was performed on 50–100ng of extracted DNA using the following
cycling conditions: 35 cycles at 941C (30s), Tm at 621C (30s) and
721C (1min), and 10% DMSO (dimethylsulphoxide). The primer
sequences for exons 1a,1 b, and 2 are listed in Table 1. Coding and
flanking intron sequences of exon 2 of the Cdk4 gene, which
include residues previously shown to be mutated in familial
melanoma (Zuo et al, 1996; Soufir et al, 1998b) were amplified
using the primer pair Cdk4F1 and Cdk4R1 (Table 1).
The PCR products were purified with the PCR product
presequencing kit according to the manufacturer’s protocol. All
fragments were sequenced with the Applied Biosystems (ABI)
BigDye Terminator Cycle Sequencing Ready Reaction Kit accord-
ing to the manufacturer’s instructions, and sequencing reactions
were analysed on an ABI 3100 automated sequencer.
INK4a-ARF deletion analysis by real-time quantitative PCR
INK4a-ARF deletion analysis was performed as recently described
for the characterisation of mono- and biallelic 9p21 deletions in
childhood acute lymphoblastic leukaemia (Bertin et al, 2003). Real-
time quantitation was performed using the SYBR Green I dye as a
fluorescent signal. The dye binds specifically to the minor groove
Table 1 PCR primers used for automated sequencing of INKA-ARF
coding exons (1a,1 b, 2, 3) and Cdk4 exon 2
Primer
localisation
Primer
name Sequences (50 –30)
Sequencing
primers
Exon 1a
p16
INK4A
P16F1 GCT CGG CGG CTG CGG AGA GG
P16R1 TCC AGA GTC GCC CGC CAT CCC
Exon 2
INK4a-ARF
P16F2 GGG TCT GCT TGG CGG TGA GG
P16R2 CGG GCT GAA CTT TCT GTG CTG GA
Exon 1b
p14
ARF
P14F1 TGC GTG GGT CCC AGT CTG CAG
P14R1 ACC GCG GTG GAG GCT TCC CAT
Exon 2
Cdk4
CDK4F1 GGA TGG GAT GCT GGT GGT GTT
CDK4R1 TTC CCT TTA CTC CCC ACG CCC
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sof double-stranded DNA, allowing the detection of PCR product
formation (Ginzinger, 2002).
Two targets were amplified on 9p21: p16
INK4a exon 3 and p14
ARF
exon 1b. One single-copy sequence was used as a reference
sequence: 8q11 SST (Single Sequence Tag), mapping at 8q11. A
volume of 5ml of DNA was added to the PCR reaction mixture
containing 1  SYBR Green buffer (Applied Biosystems), 300nM
forward and reverse primers, 5mM MgCl2 (3mM for 8q11 SST),
200mM dNTP, and 0.6U of AmpliTaq Gold (Applied Biosystems) in
a final volume of 25ml.
Each series of PCR reactions included two negative controls
containing water in place of DNA, one control containing 15ng of
HeLa DNA, and a five-point standard curve. The standard curve
was established using serial dilutions of normal PBMC in Tris
(10mM)-EDTA (1mM) buffer, ranging from 10 to 0.02ngml
 1
(corresponding to 50ng to 0.1ng of DNA analysed per well). The
same dilutions were used for all targets and reference sequences.
PCR was performed on the ABI PRISM 7700 Sequence detector
system (Applied Biosystems). All analyses were performed in
duplicate. The PCR amplification profile was as follows: initial
denaturation at 951C for 10min, followed by 40 cycles of
denaturation at 951C for 10s, and combined annealing and
extension at 651C for 1min. Detection of the fluorescent product
was carried out at the end of the extension period. To confirm
amplification specificity, the PCR products from each primer pair
were subjected to a melting-curve analysis and subsequent agarose
gel electrophoresis. The concentration of each gene was calculated
based on the respective calibration curve. The relative copy
numbers of p16
INK4a and p14
ARF were then obtained by calculating
the ratio of the result obtained for each target to the 8q11 SST
value. The normalised ratio of each target on 8q11 SST was
expected to be close to 1 if no deletion was present. Childhood
acute lymphoblastic leukaemia samples carrying somatic deletion
at the INK4a-ARF locus were used as positive controls (Bertin et al,
2003).
RESULTS
Patient characteristics
Patients were categorised into five different melanoma subgroups:
(a) familial melanoma (FAM, 23 cases), (b) multiple primary
melanoma (MPM, 18 cases), (c) melanoma and additional
unrelated cancers (13 cases), (d) age at diagnosis less than 25
years (21 cases), and (e) nonphoto-induced melanoma (NPIM, 14
cases). The numbers of patients in each group, median age at
diagnosis, patient’s nevus count, and the presence of AMS are
listed in Table 2.
Of the 23 melanoma-prone families, two had four melanoma-
affected members, five had three affected members, and 16 had two
affected members. In all, 17 families had at least two first-degree-
related affected members, whereas the six remaining families had
second-degree-related affected members. Five families (all with
two first-degree-related affected members) comprised at least one
member with multiple melanomas, and five families comprised
one patient who developed a melanoma before the age of 25 years.
Among the 18 MPM cases selected, 14 developed two
melanomas, and four developed three distinct melanomas. The
median age for the onset of the first melanoma was 42 years (range
19–70).
In total, 14 patients had a melanoma classically considered not
to be photo-induced (NPIM). Of these, three patients had a
melanoma localised on the digestive tract (anal and colon, one and
two patients, respectively). Four patients had a melanoma localised
on the buttocks, and two had a melanoma localised on the genital
organs. Four patients had an acrolentiginous melanoma, of which
three were subungual, and one was located on the sole of the foot.
One patient had a melanoma of the scalp.
Totally, 13 patients developed another cancer in addition to
melanoma: seven patients had glandular carcinomas (mammary
adenocarcinoma: three cases; thyroid carcinoma, one case;
prostate carcinoma, one case; uterus carcinoma, one case; colon
carcinoma, one case; pancreatic carcinoma, one case); four other
patients developed multiple basal cell carcinomas; one patient had
a meningioma.
Mutational analysis of INK4a-ARF and Cdk4 genes
In the present study, we identified two previously reported
mutations in the INK4a-ARF gene and five novel INK4a-ARF
mutations (Table 3).
Four mutations likely to be pathogenic were detected in three
melanoma families and in a patient who had a pancreatic cancer in
addition to melanoma.
The first mutation, present in a melanoma-prone family
comprising three affected members (FAM1), is a 24bp insertion
located at nucleotide 23 of the p16
INK4a mRNA, and is believed to
arise due to unequal crossing-over between the two 24bp repeats
naturally present in the wild-type sequence. The result is the
addition of eight (duplicated) aminoacids at the flexible N-
terminal end of the translated protein outside the ankyrin motifs,
and has also been reported to not affect p16
INK4a activity (Monzon
et al, 1998). The functional significance of this in-frame insertion is
uncertain as it occurs outside of the ankyrin domains. However, it
is noteworthy that it segregates with melanoma in four melanoma
kindreds (two in Australia, one in the UK, and one in the United
States) (Walker et al, 1995; Flores et al, 1997; Harland et al, 1997).
In our case, the mutation is present in the unaffected mother of the
proband, but unfortunately the other two melanoma-affected
members (the grandmother and her mother) could not be tested
because they are deceased.
Table 2 Characterisation of the different melanoma subgroups
MM subgroup
Number of
patients
Median age
at diagnosis
Naevus
count 450 AMS
1 FAM 23 43 (18 74) 11 (48) 4 (17)
2 MPM 18 42 (19 70) 8 (47) 4 (22)
3M M o25years 21 21 (14 25) 11 (50) 6 (28)
4 MM+other cancer 13 54 (27 76) 3 (27) 1 (8)
5 NPIM 14 58 (42 73) 4 (28) 1 (7)
MM ¼ malignant melanoma; FAM ¼ melanoma families; MPM ¼ multiple primary
melanoma; NPIM ¼ nonphoto-induced melanoma.
Table 3 INK4a-ARF germline mutations characterised in melanoma
patients
Patients
MM
subgroup
INK4a-ARF
mutation
Effect on
p16
INK4a
Effect on
p14
ARF
1 FAM Ins 24bp exon 1a Duplication —
2 FAM cCc4cGc Pro70Arg Ala84ala
3 FAM Act4Cct Thr77Pro His91Pro
4 MM+K pancreas gCc4gTc Ala57Val Arg71Arg
5M M o25years GaC4gaT Asp105Asp Arg120Cys
6M P M Gcg4Acg Ala5Thr —
7 NPIM aCa4aTan d —
 25bp atg ex 1a
The sequence is written as 50-30 for the coding strand; the mutated base is written
in uppercase letter. The text in bold indicates nucleotide and amino-acid changes.
Abbreviations: Ins ¼ insertion; MM ¼ malignant melanoma; FAM ¼ familial
melanoma; MPM ¼ multiple primary melanoma; NPIM ¼ nonphoto-induced
melanoma; n.d. ¼ not determined; — ¼ no effect.
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sThe second mutation, a C4G substitution, is located in exon 2
of the INK4a-ARF gene, and changes the p16
INK4a reading frame
(Pro70Arg), whereas it is neutral for p14
ARF (Ala84Ala; Table 3). It
was found in a family with two first-degree-related affected
members, the proband and her father (FAM2). It should be noted
that the proband developed four distinct melanomas at the ages of
38, 45, and 54 years. This mutation is localised in the sixth beta
turn of the p16
INK4a protein, connecting the second and third
ankyrin repeats, at a conserved residue (Figure 1). The replace-
ment of a proline residue by an arginine residue at this position
might therefore disturb the spatial arrangement of the two adjacent
a helixes (Figure 1).
The third mutation, an A4C substitution, is also located in
INK4a-ARF exon 2 and alters both p16
INK4a (Thr77Pro) and
p14
ARF (His91Pro) reading frames. It was found in a family with
four first-degree-related affected members (FAM3). Binding and
recognition between p16
INK4a and CDK4 or CDK6 proteins are
mediated primarily by hydrogen-bond networks (Russo et al,
1998), with several of the residues that participate in these
interactions being mutated in cancer (Figure 1). Thr77 is localised
in the second loop of p16
INK4a, in close contact with Leu33 and
Arg31 residues of CDK6 involved in p16
INK4a binding (Figures 1
and 2b). Therefore, the introduction of a proline residue at this
position is certainly deleterious because of the distortion of the
p16
INK4a tertiary structure as a consequence of a misinteraction
with the CDK4 protein. In addition, the missense mutation on
p14
ARF, His91Pro, is located in the nucleolar domain of the
protein, therefore being potentially deleterious for p14
ARF func-
tion.
The fourth mutation was detected in a patient who had a
pancreatic carcinoma in addition to cutaneous melanoma, and is
characterised by a C4T substitution at nucleotide 170 that
changes the p16
INK4a reading frame (Ala57Val), whereas it is
neutral for p14
ARF (Arg71Arg; Table 3). This mutation is located in
the second ankyrin repeat of p16
INK4a at the beginning of the a
helix (Figure 1), in close contact with conserved hydrogen-bond
networks that have a central role in CDK6 binding (Russo et al,
1998). Yet, although Ala57 is not a conserved amino acid across
species, its proximity to the alpha helix of the second ankyrin
repeat may place spatial constraints that may be altered with a
valine substitution. In addition, it has previously been described as
a germline mutation in the case of familial melanoma (Soufir et al,
1998b), and as a somatic mutation in the case of acute
lymphoblastic leukaemia (Quesnel et al, 1995), therefore being
certainly deleterious.
Three INK4a-ARF changes of uncertain significance were
detected in three patients. A C4T substitution was found in a
young melanoma patient (a woman aged 24 years). This mutation
is also localised in INK4a-ARF exon 2, but has no effect on
p16
INK4a (Asp105Asp), whereas it induces a C-terminal amino-acid
substitution (Arg120Cys) in the p14
ARF protein, at a nonconserved
codon between human and mice ARF cDNA. A missense mutation
in p16
INK4a exon 1a (substitution G4A) was found in a woman
who had two distinct melanomas. This novel mutation (Ala5Thr)
resides at the N terminus of the p16
INK4a protein and has not been
previously reported as a polymorphism in any p16
INK4a mutational
studies. Finally, a p16
INK4a variant was also found in a 64-year-old
man with an NPIM (localised on genital organs). This C4T
substitution was localised 25bp upstream from the p16
INK4a
initiator translation site and was previously described as a somatic
mutation in a skin tumour from a xeroderma pigmentosum patient
(Soufir et al, 2000), suggesting that it had a pathogenic role.
Three previously described p16
INK4a polymorphisms were
confirmed in this study. Ala148Thr was observed in seven patients
(8%). This nonsynonymous polymorphism was previously found
in 4% of the Utah population (Kamb et al, 1994), 3% of CEPH
parents (Hussussian et al, 1994), in 11% of 131 Australian
P16         1     MEPAAGSSMEPSADWLATAAARGRVEEVRALLEAG-AL 37 
P19         1         MLLEEVRAGDRLSGAAARGDVQEVRRLLHRELVH  34 
P18  1            MAEPWGNELASAAARGDLEQLTSLLQNN-VN  30 
P15  1    MREENKGMPSGGGSDEGLATPARGLVEKVRHSWEAG-AD  38 
P16 38       PN-APNSYGRRPIQVM-MMGSARVAELLLLHG-AE 69 
P19 35       PD-ALNRFGKTALQVM-MFGSTAIALELLKQG-AS  66 
P18  31       VN-AQNGFGRTALQVM-KLGNPEIARRLLLRG-AN  62 
P15  39       PN-GVNRFGRRAIQVM-MMGSARVAELLLLHG-AE  70 
P16 70       PNCADPATLTRPVHDAAREGFLDTLVVLHRAG-AR 103 
P19 67       PNVQD-TSGTSPVHDAARTGFLDTLKVLVEHG-AD  99 
P18  63       PDLKD-RTGFAVIHDAARAGFLDTLQTLLEFQ-AD  95 
P15  71       PNCADPATLTRPVHDAAREGFLDTLVVLHRAG-AR  104 
P16 104      LDVRD-AWGRLPVDLAEELGHRDVARYLRAAAGGT       137 
P19 100      VNVPD-GTGALPIHLAVQEGHTAVVSFLAAESDLH       133 
P18  96       VNIED-NEGNLPLHLAAKEGHLRVVEFLVKHTASN  129 
P15  105      LDVRD-AWGRLPVDLAEERGHRDVAGYLRTATGD  137 
P19 134       -RRD-ARGLTPLELALQRGAQDLVDILQGHMVAPL      166 
P18  130      VGHRN-HKGDTACDLARLYGREVVSLMQANGAGGATNLQ  166 
Helix Helix
Figure 1 Localisation of the p16
INK4a missense mutations within the
p16
INK4a protein. The four ankyrin repeats of human p16
INK4a are aligned
with the corresponding regions of human p18
INK4c, p19
INK4d, and p15
INK4b.
C-terminus region of p16
INK4a, p18
INK4c, and p19
INK4d were cut. Boxes
indicate the positions of the p16
INK4a mutations identified in the present
study: residue Pro70 is highly conserved, whereas residue Thr77 is
semiconserved, and Ala5 and Ala57 residues are not conserved. Filled
circles indicate localisation of other p16
INK4a mutations previously shown to
induce a loss of function. The SWISS-PROT database was used to delineate
the seven alpha helices (shaded in grey).
N-ter
C-ter
Pro70
Thr77
Thr77
N-ter
CDK6
p16INK4α
C-ter
Arg31
Leu-33
C-ter
N-ter
A
B
Figure 2 (A) Localisation in the overall p16
INK4a protein structure (PDB
2A5E) of the two p16
INK4a mutants found in FAM2 and FAM3. (B)
Localisation of p16
INK4a Threonine 77 residue in the p16
INK4a-CDK6
complex (PDB 1B17) and identification of possible partner residues in
CDK6.
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smelanoma kindreds (Holland et al, 1999), and was recently
excluded as a melanoma/nevus susceptibility allele (Bertram et al,
2002).
The G/C transversion at nucleotide 500 in the 30 untranslated
region (UTR) within exon 3 was identified in 23 of the 89 patients
(26%). This polymorphism has previously been reported to be
present in 11% of CEPH parents (Ueki et al, 1994), and found to be
associated with familial melanoma risk in Queensland (Aitken et al,
1999), but not with sporadic melanomas (Kumar et al, 2001). The
C/T polymorphism at nucleotide 540 in the 30 UTR was detected in
14 patients (allelic frequency 8.4%), at a frequency lower than the
one previously found in sporadic melanoma (14%) (Kumar et al,
2001).
Sequencing of Cdk4 exon 2 failed to detect mutations in the
coding sequence in any patient.
INK4a-ARF deletion analysis by real-time quantitative PCR
Large germline deletions are rare in familial cancers. Nevertheless,
a proportion of melanoma families linked to the 9p21 locus do not
harbour germline mutations of INK4a-ARF, and three large
deletions have been reported in hereditary predisposition to
melanoma and nervous system tumours, two involving both
p16
INK4a and p14
ARF (Bahuau et al, 1998), and one restricted to
exon 1b of p14
ARF (Randerson-Moor et al, 2001). Therefore, this
suggests that germline lesions of INK4a-ARF as a genetic
mechanism in predisposition to melanoma may need to be
reassessed. We therefore investigate p16
INK4a and p14
ARF deletion
status by using real-time quantitative PCR. The normalised ratio of
each target (exon 3 of p16
INK4a, exon 1b of p14
ARF) on 8q11 SST
was close to 1, indicating that no INK4a-ARF germline deletion was
present in any of the 71 patients examined.
DISCUSSION
To investigate more precisely the role of genetic mechanisms in the
aetiology of melanoma, we performed a mutational analysis of
INK4a-ARF and Cdk4 genes (exon 2) and a deletion analysis of
INK4a-ARF in a series of 89 cases of melanoma with suspected
hereditary predisposition. Seven patients (8%) had a total of seven
different germline changes in INK4a-ARF, in three melanoma
kindreds, and four sporadic melanomas (one melanoma associated
with a pancreatic cancer, one melanoma occurring before the age
of 25 years, one multiple primary melanoma, and one melanoma
localised to nonphoto-exposed skin). No mutation was found in
exon 2 of Cdk4.
Three p16
INK4a very likely pathogenic mutations were detected
in three out of 23 (13%) melanoma families. This mutational
frequency is lower than that previously found in French melanoma
families, 48% (Soufir et al, 1998a). Yet, the inclusion criteria in the
former study were much more stringent than in the present one;
indeed, melanoma families were selected upon stringent criteria:
more than three cases; or two cases in first-degree-related
individuals, one of them being below 50 years old, with one
additional criterion (multiple primary melanoma in one affected
member, pancreatic cancer in the family) (Soufir et al, 1998a). It
should be noted that in the present study, INK4a-ARF mutations
were found in families comprising, respectively, four, three, and
two cases of melanomas. In the latter family (FAM1), the proband
developed multiple primary melanomas. No mutations were found
in families with second-degree-related affected members. There-
fore, our study further confirms that there is a positive correlation
between the frequency of INK4a-ARF germline mutation and the
strength of family history of melanoma as recently reported
(Holland et al, 1999).
One p16
INK4a pathogenic mutation was detected in a patient who
had a melanoma associated with a pancreatic cancer, but no family
history of melanoma (Table 3). These data confirm that the
occurrence of both pancreatic cancer and melanoma, in the same
patient, signals an inherited susceptibility to cancer, and that this
predisposition is, in some cases, due to germline p16
INK4a
mutations (Lal et al, 2000). However, we found no INK4a-ARF
mutation in 12 other subjects who had a sporadic melanoma
associated with various other cancers. Although our group is too
small to draw definitive conclusions, our data are in accordance
with a recent report in which no mutation was detected in 27
melanoma patients who also had another cancer (Alao et al, 2002).
Three INK4a-ARF mutations were also found for which an
association with a genetic predisposition to melanoma remains
uncertain (Table 3), but that were devoid of 100 ADNs ethnically
matched controls previously studied (Soufir et al, 1998a). The first
one, a novel p16
INK4a missense mutation, was found in one out of
18 (5%) MPM patients. This result could be in agreement with
published reports, in which 9.6% (3/31), 11% (2/17), 9% (9/100),
and 3% (2/65) of MPM patients were carriers of INK4a-ARF
germline mutations (MacKie et al, 1998; Monzon et al, 1998;
Hashemi et al, 2000; Auroy et al, 2001). However, Ala5Thr is most
likely a polymorphism as the amino terminus of p16
INK4a prior to
the start of the ankyrin repeats is poorly conserved and is believed
to have no effect on the stability of p16
INK4a. Nevertheless, it has
recently been shown that some p16
INK4a mutants failed to induced
growth arrest despite retaining normal binding to CDK4 (Becker
et al, 2001), suggesting that p16
INK4a mutations outside the
ankyrins motifs may confer a predisposition to melanoma through
a mechanism not yet identified.
The second variant affects only the p14
ARF reading frame and
was found in one of 21 (5%) young melanoma patients without a
family history of melanoma. To date, p16
INK4a germline mutations
were characterised in only two out of 55 MM patients less than 30
years, but that both had a history of familial melanoma (Whiteman
et al, 1997; Tsao et al, 2000). Together with our data, this shows
that the INK4a-ARF gene is rarely involved in genetic predisposi-
tion to melanoma in young patients with no familial history of
melanoma. However, in the present case, a pathogenic effect of this
mutation is suggested by several data. Specific p14
ARF germline
defects were previously reported in a family with melanoma and
neural tumours and in a patient with multiple melanomas
(Randerson-Moor et al, 2001; Rizos et al, 2001b). In addition,
some of the INK4a-ARF germline mutations found in melanoma–
prone families have been shown to affect p14
ARF function (Rizos
et al, 2001a). Our mutation lies within the C-terminal p14
ARF
nucleolar localisation domain, which is essential for full p14
ARF
activity (Rizos et al, 2000). On the other hand, this mutation lies at
a nonconserved codon between mice and human ARF protein, and
therefore, may be a rare nonpathogenic variant.
The third variant is a p16
INK4a substitution located 25bp
upstream of the ATG, in the p16
INKa 50 UTR and was detected in
one of 14 patients with an NPIM. Germline mutations in critical
regions of the p16
INKa promoter could reduce or abolish promoter
function, resulting in a genetic predisposition to disease. Yet, to
date, only three variants localised in the 50UTR of p16
INKa
( 14C4T,  33 G4C,  34 G4A) have been characterised in
melanoma patients (Liu et al, 1999) (Hashemi et al, 2000) (Auroy
et al, 2001), of which only the latter one has a proved functional
effect (Liu et al, 1999). This particular mutation localised 34bp
upstream from the ATG translation initiation codon, creates an
aberrant initiation codon, and has been detected in two MPM
patients and in two melanoma families. In our case, it should be
noted that the  25 C4T substitution was previously found in a
skin squamous carcinoma from a xeroderma pigmentosum patient
(Soufir et al, 2000), suggesting that it could be pathogenic. On the
other hand, this mutation was not observed in a mutational
screening of the p16
INKa promoter in 109 melanoma families
(Harland et al, 2000), therefore raising the possibility of a rare
polymorphism, and indicating the need for functional studies of
INK4a-ARF mutations in melanoma patients
N Soufir et al
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INKa expression in order to determine whether or not promoter
single-nucleotide polymorphisms are pathogenic.
No germline mutation of Cdk4 exon 2 was detected in any
melanoma patient. This confirms previous studies performed in
melanoma families (Goldstein et al, 2002), and further shows that
the Cdk4 gene is very rarely involved in genetic predisposition to
melanoma.
We found no germline deletion of the INK4a-ARF locus in 71
melanoma patients, indicating that constitutional inactivation of
this locus by deletion is not a frequent mechanism in genetic
predisposition to melanoma.
In conclusion, our study confirms that germline mutations of
the INK4a-ARF gene are predominantly involved in genetic
predisposition to familial melanoma, particularly in large multi-
case melanoma families or in families comprising a member
affected with multiple melanomas. Other conditions, despite
suggesting a genetic predisposition to melanoma, rarely show
INK4a-ARF germline mutations. Our findings are in accordance
with the Melanoma Genetics Consortium, which considers that
melanoma patients with or without stringent familial criteria
should not be tested outside of defined research protocols (Kefford
et al, 1999, 2002).
Besides these major melanoma-predisposing genes, other
genetic predisposition factors exist. Firstly, polygenic inheritance
in combination with environmental factors such as high sun
exposure has been shown in several studies, depending upon
polymorphisms located on genes controlling DNA repair (Winsey
et al, 2000), pigmentation (Palmer et al, 2000), and reactive oxygen
detoxification pathways (Strange et al, 1999; Kanetsky et al, 2001).
Among these, loss of function variants of the human melanocortin-
1 receptor gene, which plays a crucial role in pigmentation
(Valverde et al, 1995; Bastiaens et al, 2001), seems to have an
important role in determining melanoma risk (Palmer et al, 2000;
Kennedy et al, 2001). Secondly, the possibility of mutations in
additional, as yet unidentified highly penetrant melanoma-predis-
posing genes is still a research tool.
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